Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.60 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23413408 | 0.84 | NPC1 (0.72) | KDM4ENPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL3494989 | 0.82 | NPC1 (0.70) | KDM4ENPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL6311014 | 0.81 | NPC1 (0.71) | KDM4ENPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL1563740 | 0.81 | IKBKB (0.83) | KDM4ENPC1RAB9ANPSR1MAPT | |
| SCHEMBL21259118 | 0.80 | NPC1 (0.67) | KDM4ENPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL23412899 | 0.79 | NPC1 (1.00) | KDM4ENPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL3743125 | 0.78 | NPC1 (0.64) | KDM4ENPC1RAB9ANPSR1MAPT | |
| SCHEMBL21247318 | 0.78 | NPC1 (0.71) | KDM4ENPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL1798957 | 0.77 | NPSR1 (0.66) | KDM4ENPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL6310231 | 0.77 | NPC1 (0.67) | KDM4ENPC1RAB9ANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-20200369655-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| WO-2019154953-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010088414-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | KDM4E 3493/4885NPC1 970/4885RAB9A 727/4885 |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | GRIN1, GRIN2A, GRIN2B | KDM4E 3493/4885NPC1 970/4885RAB9A 727/4885 |
| US-20200369655-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | KDM4E 2484/4885NPC1 320/4885RAB9A 1953/4885 |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | KDM4E 2484/4885NPC1 320/4885RAB9A 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.